Code for making forest plots for top GWAS loci
By onThis repository contains the script used to create forest plots for top loci .
Duplicating 96-well plate-cultured hPSCs clones
By onThis protocol describes a standard procedure for duplicating 96-well plate-cultured human pluripotent stem cells (hPSCs).
Primary data associated with doi: 10.1101/2022.04.25.489459 (A Feed-forward Pathway Drives LRRK2 kinase Membrane Recruitment and Apparent Activation)
By onRaw immunoblotting data; tabular data for quantifications; immunofluorescence images.
Immunostaining of iPSC-derived neurons
By onThe authors fix, permeabilize, and stain human iPSC-derived neurons for the purpose of observing and quantifying somal and axonal abundance of proteins of interest.
In Vivo Carbon Fiber Electrode Thread (CFET) Implantation and Testing Procedures
By onProcedures for implanting and testing CFET devices in rats are described.
Microscopy-based mitochondrial morphology measurements in iNeurons
By onAssociated with preprint: https://www.biorxiv.org/content/10.1101/2022.11.02.514817v1
pAC150-Keima-RAMP4
By onThe text describes the use of a PiggyBac vector to express the Keima-RAMP4 autophagy flux reporter, a tool for studying autophagy processes in cells.
Gene expression analysis by qPCR
By onProtocol for gene expression analysis by quantitative Real-Time PCR (qPCR).
RHReynolds/neurodegen-psych-local-corr: Code to determine local and global genetic correlations between several neurodegenerative and neuropsychiatric disorders with LAVA and LDSC, respectively.
By onCode for paper "Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases" that explores local genetic correlations among neurodegenerative and neuropsychiatric diseases.
Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation
By onThis study shows that the Lrrk2 gene affects astrocyte morphology by regulating ERM protein phosphorylation, which when reduced, restores synaptic function in PD, suggesting astrocytes as potential therapeutic targets.
H9 ES AAVS1-NGN2::TMEM192-3xHA YIPF4-/-
By onES cells modified to lack YIPF4 Golgi-phagy receptors were used to create iNeurons expressing NEUROG2. CRISPR/Cas9 was employed to introduce the construct in the AAVS1 locus of H9 ES cells.
Global lipidomics of WT and GRN-/- cells & mouse models, including plus and minus GRN addback.
By onThis dataset contains a variety of global lipidomic measurements
pCAG-MBP-Foldon-ATG9 (828-839)
By onPlasmid: To make ATG9 C-terminal tail trimer for expression in mammalian cells.
Neuromelanin staining (Fontana-Masson staining)+ TH-DAB staining on midbrain organoids
By onNeuromelanin staining (Fontana-Masson staining)+ TH-DAB staining on midbrain organoids
Expression and purification protocol of WIPI2d
By onThis protocol details the expression and purification protocol of WIPI2d.
Primary neuron culture for live imaging of axonal cargoes
By onThis protocol describes the preparation and culture of mouse primary cortical neurons for live-imaging experiments. Neurons were transfected 16-24 hours before imaging using Lipofectamine 2000.
Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach
By onPurpose of Review Genetic variants in GBA1 and LRRK2 genes are the commonest genetic risk factor for Parkinson disease (PD); however, the preclinical profile of GBA1 and LRRK2 variant carriers who will develop PD is unclear. This review aims to highlight the more sensitive markers that can stratify PD risk in non-manifesting GBA1 and LRRK2 variant carriers. Recent Findings Several case–control and a few longitudinal studies evaluated clinical, biochemical, and neuroimaging markers within cohorts of non-manifesting carriers of GBA1 and LRRK2 variants. Summary Despite similar levels of penetrance of PD in GBA1 and LRRK2 variant carriers (10–30%), these individuals have distinct preclinical profiles. GBA1 variant carriers at higher risk of PD can present with prodromal symptoms suggestive of PD (hyposmia), display increased α-synuclein levels in peripheral blood mononuclear cells, and show dopamine transporter abnormalities. LRRK2 variant carriers at higher risk of PD might show subtle motor abnormalities, but no prodromal symptoms, higher exposure to some environmental factors (non-steroid anti-inflammatory drugs), and peripheral inflammatory profile. This information will help clinicians tailor appropriate screening tests and counseling and facilitate researchers in the development of predictive markers, disease-modifying treatments, and selection of healthy individuals who might benefit from preventive interventions.
